Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 947

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Balancing repair and tolerance of DNA damage caused by alkylating agents

Open access
Fu, Dragony, Calvo, Jennifer A., Samson, Leona D.·2012·Nature Reviews Cancer
DOI 10.1038/nrc3185
Open this paper in CoChat — free account

Abstract

Alkylating agents comprise a major class of frontline chemotherapeutic drugs that inflict cytotoxic DNA damage as their main mode of action, in addition to collateral mutagenic damage. Numerous cellular pathways, including direct DNA damage reversal, base excision repair (BER), and mismatch repair (MMR) respond to alkylation damage to defend against alkylation-induced cell death or mutation. However, maintaining a proper balance of activity both within and between these pathways is crucial for an organism's favorable response to alkylating agents. Furthermore, an individual's response to alkylating agents can vary considerably from tissue to tissue and from person to person, pointing to genetic and epigenetic mechanisms that modulate alkylating agent toxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrc3185

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 202

  1. Ballschmiter, K. Pattern and sources of naturally produced organohalogens in the marine environment: biogenic formation of organohalogens. Chemosphere 52, 313–324 (2003). · DOI
  2. Hecht, S. S. DNA adduct formation from tobacco-specific N-nitrosamines. Mutat. Res. 424, 127–142 (1999). · DOI · Paper page
  3. Hamilton, J. T., McRoberts, W. C., Keppler, F., Kalin, R. M. & Harper, D. B. Chloride methylation by plant pectin: an efficient environmentally significant process. Science 301, 206–209 (2003). · DOI · Paper page
  4. Rydberg, B. & Lindahl, T. Nonenzymatic methylation of DNA by the intracellular methyl group donor S-adenosyl-L-methionine is a potentially mutagenic reaction. EMBO J. 1, 211–216 (1982). · DOI · Paper page
  5. Taverna, P. & Sedgwick, B. Generation of an endogenous DNA-methylating agent by nitrosation in Escherichia coli. J. Bacteriol. 178, 5105–5111 (1996). · DOI · Paper page
  6. Bartsch, H., O'Neill, I. K., Schulte-Hermann, R. & International Agency for Research on Cancer. Relevance of N-Nitroso Compounds to Human Cancer: Exposures and Mechanisms (Oxford Univ. Press distributor, Lyon, London, 1987).
  7. Kufe, D. W. et al. (eds) Cancer Medicine, 6th edn (BC Decker, Hamilton, Canada, 2003).
  8. Shrivastav, N., Li, D. & Essigmann, J. M. Chemical biology of mutagenesis and DNA repair: cellular responses to DNA alkylation. Carcinogenesis 31, 59–70 (2010). · DOI · Paper page
  9. Drablos, F. et al. Alkylation damage in DNA and RNA-repair mechanisms and medical significance. DNA Repair 3, 1389–1407 (2004). · DOI · Paper page
  10. Johnson, R. E., Yu, S.-L., Prakash, S. & Prakash, L. A Role for yeast and human translesion synthesis DNA polymerases in promoting replication through 3-methyl adenine. Mol. Cell. Biol. 27, 7198–7205 (2007). · DOI
  11. Engelward, B. P. et al. A chemical and genetic approach together define the biological consequences of 3-methyladenine lesions in the mammalian genome. J. Biol. Chem. 273, 5412–5418 (1998). · DOI
  12. Gate, L. & Tew, K. D. in Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures (ed. Minev, B. R.) 61–85 (Springer Netherlands, 2011). · DOI
  13. Sedgwick, B., Bates, P. A., Paik, J., Jacobs, S. C. & Lindahl, T. Repair of alkylated DNA: recent advances. DNA Repair 6, 429–442 (2007). · DOI · Paper page
  14. Samson, L., Thomale, J. & Rajewsky, M. F. Alternative pathways for the in vivo repair of O6-alkylguanine and O4-alkylthymine in Escherichia coli: the adaptive response and nucleotide excision repair. EMBO J. 7, 2261–2267 (1988). · DOI
  15. Huang, J. C., Hsu, D. S., Kazantsev, A. & Sancar, A. Substrate spectrum of human excinuclease: repair of abasic sites, methylated bases, mismatches, and bulky adducts. Proc. Natl Acad. Sci. USA 91, 12213–12217 (1994). · DOI · Paper page
  16. Kaina, B., Christmann, M., Naumann, S. & Roos, W. P. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair 6, 1079–1099 (2007). · DOI · Paper page
  17. Deans, A. J. & West, S. C. DNA interstrand crosslink repair and cancer. Nature Rev. Cancer 11, 467–480 (2011). · DOI · Paper page
  18. Kee, Y. & D'Andrea, A. D. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev. 24, 1680–1694 (2010). · DOI · Paper page
  19. Lange, S. S., Takata, K. & Wood, R. D. DNA polymerases and cancer. Nature Rev. Cancer 11, 96–110 (2011). References 16–20 describe additional pathways that are important in the repair and tolerance of DNA alkylation damage that were not described in detail in this Review. · DOI · Paper page
  20. Svilar, D., Goellner, E. M., Almeida, K. H. & Sobol, R. W. Base excision repair and lesion-dependent subpathways for repair of oxidative DNA damage. Antioxid. Redox Signal. 14, 2491–2507 (2011). · DOI · Paper page
  21. Monti, P. et al. Rev1 and Polzeta influence toxicity and mutagenicity of Me-lex, a sequence selective N3-adenine methylating agent. DNA Repair 7, 431–438 (2008). · DOI
  22. Monti, P. et al. Mutagenicity of N3-methyladenine: a multi-translesion polymerase affair. Mutat. Res. 683, 50–56 (2010). · DOI
  23. Roos, W. P. et al. The translesion polymerase Rev3L in the tolerance of alkylating anticancer drugs. Mol. Pharmacol. 76, 927–934 (2009). This paper and references 10, 22 and 23 show that TLS polymerases have a crucial role in determining alkylating agent sensitivity through the bypass of replication-blocking 3meA lesions. · DOI
  24. Prasad, R., Shock, D. D., Beard, W. A. & Wilson, S. H. Substrate channeling in mammalian base excision repair pathways: passing the baton. J. Biol. Chem. 285, 40479–40488 (2010). · DOI
  25. Mol, C. D., Izumi, T., Mitra, S. & Tainer, J. A. DNA-bound structures and mutants reveal abasic DNA binding by APE1 DNA repair and coordination. Nature 403, 451–456 (2000). The structural and mutational analysis described in this paper provided the basis of the mechanism that toxic BER intermediates are passed from one BER enzyme to another, as reviewed in reference 25. · DOI · Paper page
  26. Sieber, O. M. et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N. Engl. J. Med. 348, 791–799 (2003). · DOI · Paper page
  27. Fleischmann, C. et al. Comprehensive analysis of the contribution of germline MYH variation to early-onset colorectal cancer. Int. J. Cancer 109, 554–558 (2004). · DOI
  28. Rusyn, I. et al. Transcriptional networks in S. cerevisiae linked to an accumulation of base excision repair intermediates. PLoS ONE 2, e1252 (2007). · DOI
  29. Meira, L. B. et al. Aag-initiated base excision repair drives alkylation-induced retinal degeneration in mice. Proc. Natl Acad. Sci. USA 106, 888–893 (2009). This paper was the first to illustrate that deficiency of a DNA glycosylase in vivo results in protection from alkylation damage, specifically MMS-mediated retinal degeneration. · DOI
  30. Sobol, R. W. et al. Base excision repair intermediates induce p53-independent cytotoxic and genotoxic responses. J. Biol. Chem. 278, 39951–39959 (2003). · DOI · Paper page
  31. Fishel, M. L., He, Y., Smith, M. L. & Kelley, M. R. Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. Clin. Cancer Res. 13, 260–267 (2007). · DOI
  32. Kaasen, I., Evensen, G. & Seeberg, E. Amplified expression of the tag+ and alkA+ genes in Escherichia coli: identification of gene products and effects on alkylation resistance. J. Bacteriol. 168, 642–647 (1986). · DOI
  33. Xiao, W. & Samson, L. In vivo evidence for endogenous DNA alkylation damage as a source of spontaneous mutation in eukaryotic cells. Proc. Natl Acad. Sci. USA 90, 2117–2121 (1993). · DOI · Paper page
  34. Glassner, B. J., Rasmussen, L. J., Najarian, M. T., Posnick, L. M. & Samson, L. D. Generation of a strong mutator phenotype in yeast by imbalanced base excision repair. Proc. Natl Acad. Sci. USA 95, 9997–10002 (1998). References 33–35 illustrate that BER intermediates are toxic and mutagenic; an imbalance in the BER pathway results in increased mutagenesis, as well as in enhanced alkylation sensitivity. · DOI · Paper page
  35. Posnick, L. M. & Samson, L. D. Imbalanced base excision repair increases spontaneous mutation and alkylation sensitivity in Escherichia coli. J. Bacteriol. 181, 6763–6771 (1999). · doi:10.1128/jb.181.21.6763-6771.1999
  36. Calleja, F., Jansen, J. G., Vrieling, H., Laval, F. & van Zeeland, A. A. Modulation of the toxic and mutagenic effects induced by methyl methanesulfonate in Chinese hamster ovary cells by overexpression of the rat N-alkylpurine-DNA glycosylase. Mutat. Res. 425, 185–194 (1999). · doi:10.1016/s0027-5107(99)00034-2
  37. Rinne, M., Caldwell, D. & Kelley, M. R. Transient adenoviral N-methylpurine DNA glycosylase overexpression imparts chemotherapeutic sensitivity to human breast cancer cells. Mol. Cancer Ther. 3, 955–967 (2004). · DOI
  38. Rinne, M. L., He, Y., Pachkowski, B. F., Nakamura, J. & Kelley, M. R. N-methylpurine DNA glycosylase overexpression increases alkylation sensitivity by rapidly removing non-toxic 7-methylguanine adducts. Nucleic Acids Res. 33, 2859–2867 (2005). · DOI
  39. Trivedi, R. N. et al. Human methyl purine DNA glycosylase and DNA polymerase β expression collectively predict sensitivity to temozolomide. Mol. Pharmacol. 74, 505–516 (2008). · DOI
  40. Coquerelle, T., Dosch, J. & Kaina, B. Overexpression of N-methylpurine-DNA glycosylase in Chinese hamster ovary cells renders them more sensitive to the production of chromosomal aberrations by methylating agents-a case of imbalanced DNA repair. Mutat. Res. 336, 9–17 (1995). · DOI
  41. Klapacz, J. et al. Frameshift mutagenesis and microsatellite instability induced by human alkyladenine DNA glycosylase. Mol. Cell 37, 843–853 (2010). · DOI
  42. Hofseth, L. J. et al. The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J. Clin. Invest. 112, 1887–1894 (2003). This paper clearly describes a correlation between imbalanced BER and microsatellite instability in human tissues. · DOI · Paper page
  43. Cerda, S. R., Turk, P. W., Thor, A. D. & Weitzman, S. A. Altered expression of the DNA repair protein, N-methylpurine-DNA glycosylase (MPG) in breast cancer. FEBS Lett. 431, 12–18 (1998). · DOI
  44. Curtis, C. D., Thorngren, D. L. & Nardulli, A. M. Immunohistochemical analysis of oxidative stress and DNA repair proteins in normal mammary and breast cancer tissues. BMC Cancer 10, 9 (2010). · DOI
  45. Kim, N. K. et al. Expression of the DNA repair enzyme, N-methylpurine-DNA glycosylase (MPG) in astrocytic tumors. Anticancer Res. 23, 1417–1423 (2003).
  46. Mirabello, L. et al. A comprehensive candidate gene approach identifies genetic variation associated with osteosarcoma. BMC Cancer 11, 209 (2011). · DOI
  47. Elder, R. H. et al. Alkylpurine-DNA-N-glycosylase knockout mice show increased susceptibility to induction of mutations by methyl methanesulfonate. Mol. Cell. Biol. 18, 5828–5837 (1998). · DOI
  48. Engelward, B. P. et al. Base excision repair deficient mice lacking the Aag alkyladenine DNA glycosylase. Proc. Natl Acad. Sci. USA 94, 13087–13092 (1997). · DOI · Paper page
  49. Roth, R. B. & Samson, L. D. 3-Methyladenine DNA glycosylase-deficient Aag null mice display unexpected bone marrow alkylation resistance. Cancer Res. 62, 656–660 (2002). This paper reports the surprising discovery that AAG deficiency can protect against MMS toxicity in ex vivo bone marrow assays.
  50. Cardinal, J. W. et al. Increased susceptibility to streptozotocin-induced β-cell apoptosis and delayed autoimmune diabetes in alkylpurine-DNA-N-glycosylase-deficient mice. Mol. Cell. Biol. 21, 5605–5613 (2001). · DOI
  51. Burns, N. & Gold, B. The effect of 3-methyladenine DNA glycosylase-mediated DNA repair on the induction of toxicity and diabetes by the β-cell toxicant streptozotocin. Toxicol. Sci. 95, 391–400 (2007). · DOI
  52. Paik, J., Duncan, T., Lindahl, T. & Sedgwick, B. Sensitization of human carcinoma cells to alkylating agents by small interfering RNA suppression of 3-alkyladenine-DNA glycosylase. Cancer Res. 65, 10472–10477 (2005). · DOI
  53. Engelward, B. P. et al. Repair-deficient 3-methyladenine DNA glycosylase homozygous mutant mouse cells have increased sensitivity to alkylation-induced chromosome damage and cell killing. EMBO J. 15, 945–952 (1996). References 49 and 54 describe the generation of Aag−/− embryonic stem cells and Aag−/− mice, and show that in certain cell types AAG deficiency results in increased alkylation sensitivity. · DOI · Paper page
  54. Wirtz, S. et al. Both base excision repair and O6-methylguanine-DNA methyltransferase protect against methylation-induced colon carcinogenesis. Carcinogenesis 31, 2111–2117 (2010). · DOI
  55. Meira, L. B. et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J. Clin. Invest. 118, 2516–2525 (2008).
  56. Liu, L., Taverna, P., Whitacre, C. M., Chatterjee, S. & Gerson, S. L. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin. Cancer Res. 5, 2908–2917 (1999).
  57. Loeb, L. A. & Preston, B. D. Mutagenesis by Apurinic/Apyrimidinic Sites. Annu. Rev. Genet. 20, 201–230 (1986). · DOI · Paper page
  58. Kunz, B. A. et al. Specificity of the mutator caused by deletion of the yeast structural gene (APN1) for the major apurinic endonuclease. Proc. Natl Acad. Sci. USA 91, 8165–8169 (1994). · DOI
  59. Luo, M. & Kelley, M. R. Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. Anticancer Res. 24, 2127–2134 (2004).
  60. Wang, D., Luo, M. & Kelley, M. R. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol. Cancer Ther. 3, 679–686 (2004). · DOI · Paper page
  61. Taverna, P. et al. Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells. Mutat. Res. 485, 269–281 (2001). · DOI
  62. Wilson, D. & Simeonov, A. Small molecule inhibitors of DNA repair nuclease activities of APE1. Cell. Mol. Life Sci. 67, 3621–3631 (2010). · DOI
  63. Sobol, R. W. et al. Requirement of mammalian DNA polymerase-β in base-excision repair. Nature 379, 183–186 (1996). · DOI · Paper page
  64. Cabelof, D. C. et al. Base excision repair deficiency caused by polymerase β haploinsufficiency: accelerated DNA damage and increased mutational response to carcinogens. Cancer Res. 63, 5799–5807 (2003).
  65. Sobol, R. W. et al. Mutations associated with base excision repair deficiency and methylation-induced genotoxic stress. Proc. Natl Acad. Sci. USA 99, 6860–6865 (2002). · DOI
  66. Poltoratsky, V., Horton, J. K., Prasad, R. & Wilson, S. H. REV1 mediated mutagenesis in base excision repair deficient mouse fibroblast. DNA Repair 4, 1182–1188 (2005). · DOI
  67. Horton, J. K., Joyce-Gray, D. F., Pachkowski, B. F., Swenberg, J. A. & Wilson, S. H. Hypersensitivity of DNA polymerase β null mouse fibroblasts reflects accumulation of cytotoxic repair intermediates from site-specific alkyl DNA lesions. DNA Repair 2, 27–48 (2003). · DOI
  68. Sobol, R. W. et al. The lyase activity of the DNA repair protein β-polymerase protects from DNA-damage-induced cytotoxicity. Nature 405, 807–810 (2000). Reference 64 illustrates how Pol β is required for BER and that Pol β deficiency results in hypersensitivity to alkylating agents. Mutational analysis described in reference 69 demonstrates that the 5′-dRP lyase activity of Pol β is sufficient to protect against alkylating agent toxicity. · DOI · Paper page
  69. Wang, L., Bhattacharyya, N., Rabi, T. & Banerjee, S. Mammary carcinogenesis in transgenic mice expressing a dominant-negative mutant of DNA polymerase β in their mammary glands. Carcinogenesis 28, 1356–1363 (2007). · DOI
  70. Chan, K. et al. Overexpression of DNA polymerase β results in an increased rate of frameshift mutations during base excision repair. Mutagenesis 22, 183–188 (2007). · DOI
  71. Yamada, N. A. & Farber, R. A. Induction of a low level of microsatellite instability by overexpression of DNA polymerase β. Cancer Res. 62, 6061–6064 (2002).
  72. Almeida, K. H. & Sobol, R. W. A unified view of base excision repair: lesion-dependent protein complexes regulated by post-translational modification. DNA Repair 6, 695–711 (2007). · DOI · Paper page
  73. Ström, C. E. et al. Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res. 39, 3166–3175 (2010). · DOI · Paper page
  74. Zdzienicka, M. Z. et al. A Chinese hamster ovary cell mutant (EM-C11) with sensitivity to simple alkylating agents and a very high level of sister chromatid exchanges. Mutagenesis 7, 265–269 (1999). · DOI
  75. Horton, J. K. et al. XRCC1 and DNA polymerase β in cellular protection against cytotoxic DNA single-strand breaks. Cell Res. 18, 48–63 (2008). · DOI · Paper page
  76. Briegert, M. & Kaina, B. Human monocytes, but not dendritic cells derived from them, are defective in base excision repair and hypersensitive to methylating agents. Cancer Res. 67, 26–31 (2007). · DOI
  77. Jiang, Y., Zhou, S., Sandusky, G. E., Kelley, M. R. & Fishel, M. L. Reduced expression of DNA repair and redox signaling protein APE1/Ref-1 impairs human pancreatic cancer cell survival, proliferation, and cell cycle progression. Cancer Invest. 28, 885–895 (2010). · DOI
  78. Al-Attar, A. et al. Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers. Br. J. Cancer 102, 704–709 (2010). · DOI
  79. Di Maso, V. et al. Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. Mol. Med. 13, 89–96 (2007). · DOI
  80. Freitas, S., Moore, D. H., Michael, H. & Kelley, M. R. Studies of apurinic/apyrimidinic endonuclease/ref-1 expression in epithelial ovarian cancer. Clin. Cancer Res. 9, 4689–4694 (2003).
  81. Kakolyris, S. et al. Nuclear localization of human AP endonuclease 1 (HAP1/Ref-1) associates with prognosis in early operable non-small cell lung cancer (NSCLC). The J. Pathol. 189, 351–357 (1999). · doi:10.1002/(sici)1096-9896(199911)189:3<351::aid-path435>3.0.co;2-1
  82. Sweasy, J. B., Lang, T. & DiMaio, D. Is base excision repair a tumor suppressor mechanism? Cell Cycle 5, 250–259 (2006). · DOI
  83. Starcevic, D., Dalal, S. & Sweasy, J. B. Is there a link between DNA polymerase β and cancer? Cell Cycle 3, 996–999 (2004). · DOI · Paper page
  84. Jiang, J., Zhang, X., Yang, H. & Wang, W. Polymorphisms of DNA repair genes: ADPRT, XRCC1, and XPD and cancer risk in genetic epidemiology. Methods Mol. Biol. 471, 305–333 (2009). · DOI
  85. Simeonov, A. et al. Identification and characterization of inhibitors of human apurinic/apyrimidinic endonuclease APE1. PLoS ONE 4, e5740 (2009). · DOI
  86. Bapat, A. et al. Novel small-molecule inhibitor of apurinic/apyrimidinic endonuclease 1 blocks proliferation and reduces viability of glioblastoma cells. J. Pharmacol. Exp. Ther. 334, 988–998 (2010). · DOI
  87. Tang, J.-b. et al. N-methylpurine DNA glycosylase and DNA polymerase β modulate BER inhibitor potentiation of glioma cells to temozolomide. Neuro Oncol. 13, 471–486 (2011). · DOI
  88. Liu, L. & Gerson, S. L. Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Curr. Opin. Investig. Drugs 5, 623–627 (2004).
  89. Jiang, Y. et al. Role of APE1 in differentiated neuroblastoma SH-SY5Y cells in response to oxidative stress: use of APE1 small molecule inhibitors to delineate APE1 functions. DNA Repair 8, 1273–1282 (2009). · DOI
  90. Izumi, T. et al. Two essential but distinct functions of the mammalian abasic endonuclease. Proc. Natl Acad. Sci. USA 102, 5739–5743 (2005). This study clearly showed that APE contains two domains with independent functions, both of which are essential for cell survival. · DOI · Paper page
  91. Wilson, S. et al. Base excision repair and design of small molecule inhibitors of human DNA polymerase β. Cell. Mol. Life Sci. 67, 3633–3647 (2010). References 89 and 92 illustrate the strategies and progress made in developing drugs that inhibit BER as cancer chemotherapeutic agents. · DOI
  92. Hu, H. Y. et al. Identification of small molecule synthetic inhibitors of DNA polymerase β by NMR chemical shift mapping. J. Biol. Chem. 279, 39736–39744 (2004). · doi:10.1074/jbc.m402842200
  93. Jaiswal, A. S. et al. A novel inhibitor of DNA polymerase β enhances the ability of temozolomide to impair the growth of colon cancer cells. Mol. Cancer Res. 7, 1973–1983 (2009). · DOI
  94. Jaiswal, A. S. et al. DNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancer. PLoS ONE 6, e16691 (2011). · DOI
  95. Stachelek, G. C. et al. Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase β is accentuated by BRCA2 mutation. Cancer Res. 70, 409–417 (2010). · DOI
  96. Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H. & Poirier, G. G. PARP inhibition: PARP1 and beyond. Nature Rev. Cancer 10, 293–301 (2010). · DOI · Paper page
  97. Mégnin-Chanet, F., Bollet, M. & Hall, J. Targeting poly(ADP-ribose) polymerase activity for cancer therapy. Cell. Mol. Life Sci. 67, 3649–3662 (2010). · DOI
  98. de Murcia, J. M. et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc. Natl Acad. Sci. USA 94, 7303–7307 (1997). · DOI · Paper page
  99. Shibata, A. et al. Parp-1 deficiency causes an increase of deletion mutations and insertions/rearrangements in vivo after treatment with an alkylating agent. Oncogene 24, 1328–1337 (2005). · DOI
  100. Jelezcova, E. et al. Parp1 activation in mouse embryonic fibroblasts promotes Pol β-dependent cellular hypersensitivity to alkylation damage. Mutat. Res. 686, 57–67 (2010). · DOI
  101. Kelley, M. R. DNA repair inhibitors: where do we go from here? DNA Repair 10, 1183–1185 (2011). · doi:10.1016/j.dnarep.2011.09.003
  102. Pegg, A. E. Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools. Chem. Res. Toxicol. 24, 618–639 (2011). · DOI · Paper page
  103. Nakatsuru, Y. et al. O6-methylguanine-DNA methyltransferase protects against nitrosamine-induced hepatocarcinogenesis. Proc. Natl Acad. Sci. USA 90, 6468–6472 (1993). · DOI
  104. Dumenco, L. L., Allay, E., Norton, K. & Gerson, S. L. The prevention of thymic lymphomas in transgenic mice by human O6-alkylguanine-DNA alkyltransferase. Science 259, 219–222 (1993). References 106 and 107 were the first to demonstrate that transgenic overexpression of MGMT in mice confers resistance to alkylating agent-induced carcinogenesis and reduced tumour formation. · DOI · Paper page
  105. Liu, L., Allay, E., Dumenco, L. L. & Gerson, S. L. Rapid repair of O6-methylguanine-DNA adducts protects transgenic mice from N-methylnitrosourea-induced thymic lymphomas. Cancer Res. 54, 4648–4652 (1994).
  106. Allay, E., Veigl, M. & Gerson, S. L. Mice over-expressing human O6 alkylguanine-DNA alkyltransferase selectively reduce O6 methylguanine mediated carcinogenic mutations to threshold levels after N-methyl-N-nitrosourea. Oncogene 18, 3783–3787 (1999). · doi:10.1038/sj.onc.1202697
  107. Zhou, Z. Q. et al. Spontaneous hepatocellular carcinoma is reduced in transgenic mice overexpressing human O6- methylguanine-DNA methyltransferase. Proc. Natl Acad. Sci. USA 98, 12566–12571 (2001). · DOI
  108. Zaidi, N. H. et al. Transgenic expression of human MGMT protects against azoxymethane-induced aberrant crypt foci and G to A mutations in the K-ras oncogene of mouse colon. Carcinogenesis 16, 451–456 (1995). · DOI
  109. Becker, K., Dosch, J., Gregel, C. M., Martin, B. A. & Kaina, B. Targeted expression of human O6-methylguanine-DNA methyltransferase (MGMT) in transgenic mice protects against tumor initiation in two-stage skin carcinogenesis. Cancer Res. 56, 3244–3249 (1996).
  110. Becker, K. et al. DNA repair protein MGMT protects against N-methyl-N-nitrosourea-induced conversion of benign into malignant tumors. Carcinogenesis 24, 541–546 (2003). · DOI
  111. Becker, K., Gregel, C. M. & Kaina, B. The DNA repair protein O6-methylguanine-DNA methyltransferase protects against skin tumor formation induced by antineoplastic chloroethylnitrosourea. Cancer Res. 57, 3335–3338 (1997).
  112. Allay, E. et al. Potentiation of lymphomagenesis by methylnitrosourea in mice transgenic for LMO1 is blocked by O6-alkylguanine DNA-alkyltransferase. Oncogene 15, 2127–2132 (1997). · DOI
  113. Qin, X., Zhou, H., Liu, L. & Gerson, S. L. Transgenic expression of human MGMT blocks the hypersensitivity of PMS2-deficient mice to low dose MNU thymic lymphomagenesis. Carcinogenesis 20, 1667–1673 (1999). · doi:10.1093/carcin/20.9.1667
  114. Qin, X., Liu, L. & Gerson, S. L. Mice defective in the DNA mismatch gene PMS2 are hypersensitive to MNU induced thymic lymphoma and are partially protected by transgenic expression of human MGMT. Oncogene 18, 4394–4400 (1999). · DOI
  115. Reese, J. S., Allay, E. & Gerson, S. L. Overexpression of human O6-alkylguanine DNA alkyltransferase (AGT) prevents MNU induced lymphomas in heterozygous p53 deficient mice. Oncogene 20, 5258–5263 (2001). · DOI
  116. Kisby, G. E. et al. DNA repair modulates the vulnerability of the developing brain to alkylating agents. DNA Repair 8, 400–412 (2009). · DOI
  117. Tsuzuki, T. et al. Targeted disruption of the DNA repair methyltransferase gene renders mice hypersensitive to alkylating agent. Carcinogenesis 17, 1215–1220 (1996). · DOI
  118. Glassner, B. J. et al. DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents. Mutagenesis 14, 339–347 (1999). · DOI
  119. Klapacz, J. et al. O6-methylguanine-induced cell death involves exonuclease 1 as well as DNA mismatch recognition in vivo. Proc. Natl Acad. Sci. USA 106, 576–581 (2009). · DOI
  120. Reese, J. S., Qin, X., Ballas, C. B., Sekiguchi, M. & Gerson, S. L. MGMT expression in murine bone marrow is a major determinant of animal survival after alkylating agent exposure. J. Hematother. Stem Cell Res. 10, 115–123 (2001). · doi:10.1089/152581601750098354
  121. Sakumi, K. et al. Methylnitrosourea-induced tumorigenesis in MGMT gene knockout mice. Cancer Res. 57, 2415–2418 (1997).
  122. Iwakuma, T. et al. High incidence of nitrosamine-induced tumorigenesis in mice lacking DNA repair methyltransferase. Carcinogenesis 18, 1631–1635 (1997). · DOI
  123. Hansen, R. J., Nagasubramanian, R., Delaney, S. M., Samson, L. D. & Dolan, M. E. Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice. Carcinogenesis 28, 1111–1116 (2007). · DOI
  124. Christmann, M., Verbeek, B., Roos, W. P. & Kaina, B. O6-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry. Biochim. Biophys. Acta 1816, 179–190 (2011). This comprehensive review summarizes the vast number of studies on MGMT expression, activity and promoter methylation in human tissues and cancers.
  125. Hongeng, S. et al. O6-Methylguanine-DNA methyltransferase protein levels in pediatric brain tumors. Clin. Cancer Res. 3, 2459–2463 (1997).
  126. Bobola, M. S. et al. O6-methylguanine-DNA methyltransferase in pediatric primary brain tumors. Clin. Cancer Res. 7, 613–619 (2001).
  127. Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997–1003 (2005). · DOI · Paper page
  128. Christmann, M. et al. MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. Int. J. Cancer 127, 2106–2118 (2010). · DOI
  129. Kaina, B., Margison, G. & Christmann, M. Targeting O6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cell. Mol. Life Sci. 67, 3663–3681 (2010). · DOI
  130. Weingart, J. et al. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J. Clin. Oncol. 25, 399–404 (2007). · doi:10.1200/jco.2006.06.6290
  131. Quinn, J. A. et al. Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J. Clin. Oncol. 27, 1262–1267 (2009). · DOI · Paper page
  132. Batts, E. et al. O6-benzylguanine and BCNU in multiple myeloma: a phase II trial. Cancer Chemother. Pharmacol. 60, 415–421 (2007). · DOI
  133. Gajewski, T. F. et al. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Clin. Cancer Res. 11, 7861–7865 (2005). · DOI
  134. Moritz, T., Mackay, W., Glassner, B. J., Williams, D. A. & Samson, L. Retrovirus-mediated expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea-induced toxicity in vitro and in vivo. Cancer Res. 55, 2608–2614 (1995).
  135. Maze, R. et al. Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent. Proc. Natl Acad. Sci. USA 93, 206–210 (1996). References 137 and 138 show that transplantation of bone marrow cells overexpressing MGMT can suppress alkylating agent myelosuppression and toxicity in mice. · doi:10.1073/pnas.93.1.206
  136. Jelinek, J. et al. Long-term protection of hematopoiesis against the cytotoxic effects of multiple doses of nitrosourea by retrovirus-mediated expression of human O6-alkylguanine-DNA-alkyltransferase. Blood 87, 1957–1961 (1996). · doi:10.1182/blood.v87.5.1957.1957
  137. Allay, J. A., Koç, O. N., Davis, B. M. & Gerson, S. L. Retroviral-mediated gene transduction of human alkyltransferase complementary DNA confers nitrosourea resistance to human hematopoietic progenitors. Clin. Cancer Res. 2, 1353–1359 (1996).
  138. Schambach, A. & Baum, C. Vector design for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. DNA Repair 6, 1187–1196 (2007). · DOI
  139. Neff, T. et al. Methylguanine methyltransferase–mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. J. Clin. Invest. 112, 1581–1588 (2003). · doi:10.1172/jci200318782
  140. Maze, R., Hanenberg, H. & Williams, D. A. Establishing chemoresistance in hematopoietic progenitor cells. Mol. Med. Today 3, 350–358 (1997). · doi:10.1016/s1357-4310(97)01094-0
  141. Ragg, S., Xu-Welliver, M. & Bailey, J. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res. 60, 5187–5195 (2000).
  142. Jansen, M. et al. Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMTP140K into hematopoietic stem cells. Cancer Gene Ther. 9, 737–746 (2002). · doi:10.1038/sj.cgt.7700490
  143. Neff, T. et al. Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood 105, 997–1002 (2005). · DOI
  144. Reha-Krantz, L. J., Nonay, R. L., Day, R. S. & Wilson, S. H. Replication of O6-methylguanine-containing DNA by repair and replicative DNA polymerases. J. Biol. Chem. 271, 20088–20095 (1996). · DOI
  145. Haracska, L., Prakash, S. & Prakash, L. Replication past O6-methylguanine by yeast and human DNA polymerase eta. Mol. Cell. Biol. 20, 8001–8007 (2000). · DOI
  146. Choi, J. Y. et al. Translesion synthesis across O6-alkylguanine DNA adducts by recombinant human DNA polymerases. J. Biol. Chem. 281, 38244–38256 (2006). · DOI
  147. Takenaka, K. et al. Involvement of vertebrate Polκ in translesion DNA synthesis across DNA monoalkylation damage. J. Biol. Chem. 281, 2000–2004 (2006). · DOI
  148. Haracska, L., Prakash, S. & Prakash, L. Yeast DNA polymerase ζ is an efficient extender of primer ends opposite from 7,8-dihydro-8-oxoguanine and O6-methylguanine. Mol. Cell. Biol. 23, 1453–1459 (2003). · DOI
  149. Haracska, L., Prakash, L. & Prakash, S. Role of human DNA polymerase κ as an extender in translesion synthesis. Proc. Natl Acad. Sci. USA 99, 16000–16005 (2002). · DOI · Paper page
  150. Kaina, B., Gerhard, F., Sankar, M. & Coquerelle, T. Transfection and expression of human O6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents. Carcinogenesis 12, 1857–1867 (1991). · DOI · Paper page
  151. Lips, J. & Kaina, B. Repair of O6-methylguanine is not affected by thymine base pairing and the presence of MMR proteins. DNA Repair 487, 59–66 (2001). · doi:10.1016/s0921-8777(01)00105-7
  152. Casorelli I, Russo MT & M., B. Role of mismatch repair and MGMT in response to anticancer therapies. Anticancer Agents Med. Chem. 8, 368–380 (2008). · DOI
  153. Duckett, D. R. et al. Human MutSα recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc. Natl Acad. Sci. USA 93, 6443–6447 (1996). · DOI · Paper page
  154. Meikrantz, W., Bergom, M. A., Memisoglu, A. & Samson, L. O6-alkylguanine DNA lesions trigger apoptosis. Carcinogenesis 19, 369–372 (1998). · DOI
  155. Rasmussen, L. J. & Samson, L. The Escherichia coli MutS DNA mismatch binding protein specifically binds O6-methylguanine DNA lesions. Carcinogenesis 17, 2085–2088 (1996). References 156 and 158 provide a direct link between the MMR pathway and alkylation damage by showing that MUTS and MUTSα can directly recognize O6meG lesions. · doi:10.1093/carcin/17.9.2085
  156. Dosch, J., Christmann, M. & Kaina, B. Mismatch G-T binding activity and MSH2 expression is quantitatively related to sensitivity of cells to methylating agents. Carcinogenesis 19, 567–573 (1998). · DOI
  157. Hickman, M. J. & Samson, L. D. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc. Natl Acad. Sci. USA 96, 10764–10769 (1999). · DOI · Paper page
  158. Mojas, N., Lopes, M. & Jiricny, J. Mismatch repair-dependent processing of methylation damage gives rise to persistent single-stranded gaps in newly replicated DNA. Genes Dev. 21, 3342–3355 (2007). · DOI · Paper page
  159. Ochs, K. & Kaina, B. Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res. 60, 5815–5824 (2000). References 161 and 162 provide evidence that MMR-dependent processing of O6meG gives rise to cytotoxic DSBs that trigger apoptotic cell death.
  160. Rajesh, P., Rajesh, C., Wyatt, M. D. & Pittman, D. L. RAD51D protects against MLH1-dependent cytotoxic responses to O6-methylguanine. DNA Repair 9, 458–467 (2010). · DOI
  161. Roos, W. P. et al. Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O6-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs. DNA Repair 8, 72–86 (2009). · DOI
  162. Cejka, P. & Jiricny, J. Interplay of DNA repair pathways controls methylation damage toxicity in saccharomyces cerevisiae. Genetics 179, 1835–1844 (2008). · DOI
  163. Mirzoeva, O. K., Kawaguchi, T. & Pieper, R. O. The Mre11/Rad50/Nbs1 complex interacts with the mismatch repair system and contributes to temozolomide-induced G2 arrest and cytotoxicity. Mol. Cancer Ther. 5, 2757–2766 (2006). · DOI
  164. Tsaryk, R., Fabian, K., Thacker, J. & Kaina, B. Xrcc2 deficiency sensitizes cells to apoptosis by MNNG and the alkylating anticancer drugs temozolomide, fotemustine and mafosfamide. Cancer Lett. 239, 305–313 (2006). · DOI
  165. Eich, M., Roos, W. P., Dianov, G. L., Digweed, M. & Kaina, B. Nijmegen breakage syndrome protein (NBN) causes resistance to methylating anticancer drugs such as temozolomide. Mol. Pharmacol. 78, 943–951 (2010). · DOI
  166. Kaina, B. The interrelationship between SCE induction, cell survival, mutagenesis, aberration formation and DNA synthesis inhibition in V79 cells treated with N-methyl-N-nitrosourea or N-methyl-N'-nitro-N-nitrosoguanidine. Mutat. Res. 142, 49–54 (1985). · doi:10.1016/s0165-7992(85)80012-9
  167. Branch, P., Aquilina, G., Bignami, M. & Karran, P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 362, 652–654 (1993). · DOI · Paper page
  168. Koi, M. et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res. 54, 4308–4312 (1994).
  169. de Wind, N., Dekker, M., Berns, A., Radman, M. & te Riele, H. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell 82, 321–330 (1995). References 171–173 show that loss of MMR confers resistance to alkylating agent toxicity in both cells and animals, providing conclusive evidence for the hypothesis that inappropriate MMR-dependent processing of O6meG is a major cytotoxic event associated with alkylating agents. · DOI · Paper page
  170. Andrew, S. E. et al. Tissues of MSH2-deficient mice demonstrate hypermutability on exposure to a DNA methylating agent. Proc. Natl Acad. Sci. USA 95, 1126–1130 (1998). · DOI
  171. Hickman, M. J. & Samson, L. D. Apoptotic signaling in response to a single type of DNA lesion, O6-methylguanine. Mol. Cell 14, 105–116 (2004). · DOI
  172. Toft, N. J. et al. Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine. Proc. Natl Acad. Sci. USA 96, 3911–3915 (1999). · DOI · Paper page
  173. Sansom, O. J., Toft, N. J., Winton, D. J. & Clarke, A. R. Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent manner. Oncogene 20, 3580–3584 (2001). · DOI
  174. Sansom, O. J. & Clarke, A. R. The ability to engage enterocyte apoptosis does not predict long-term crypt survival in p53 and Msh2 deficient mice. Oncogene 21, 5934–5939 (2002). · doi:10.1038/sj.onc.1205760
  175. Reese, J. S., Liu, L. & Gerson, S. L. Repopulating defect of mismatch repair-deficient hematopoietic stem cells. Blood 102, 1626–1633 (2003). · DOI
  176. Sansom, O. J. et al. Apoptosis and mutation in the murine small intestine: loss of Mlh1- and Pms2-dependent apoptosis leads to increased mutation in vivo. DNA Repair 2, 1029–1039 (2003). · doi:10.1016/s1568-7864(03)00111-3
  177. Bugni, J. M., Meira, L. B. & Samson, L. D. Alkylation-induced colon tumorigenesis in mice deficient in the Mgmt and Msh6 proteins. Oncogene 28, 734–741 (2009). · DOI
  178. Kawate, H. et al. A defect in a single allele of the Mlh1 gene causes dissociation of the killing and tumorigenic actions of an alkylating carcinogen in methyltransferase-deficient mice. Carcinogenesis 21, 301–305 (2000). · DOI
  179. Stallons, L. J. & McGregor, W. G. Translesion synthesis polymerases in the prevention and promotion of carcinogenesis. J. Nucleic Acids 2010, 1–10 (2010). · DOI
  180. Moynahan, M. E. & Jasin, M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nature Rev. Mol. Cell Biol. 11, 196–207 (2010). · DOI · Paper page
  181. Arana, M. E. & Kunkel, T. A. Mutator phenotypes due to DNA replication infidelity. Semin. Cancer Biol. 20, 304–311 (2010). · DOI
  182. Hewish, M., Lord, C. J., Martin, S. A., Cunningham, D. & Ashworth, A. Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nature Rev. Clin. Oncol. 7, 197–208 (2010). · DOI · Paper page
  183. Trainer, A. H. et al. The role of BRCA mutation testing in determining breast cancer therapy. Nature Rev. Clin. Oncol. 7, 708–717 (2010). · DOI
  184. Valeri, N. et al. Modulation of mismatch repair and genomic stability by miR-155. Proc. Natl Acad. Sci. USA 107, 6982–6987 (2010). · DOI · Paper page
  185. Moskwa, P. et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol. Cell 41, 210–220 (2011). This study shows that microRNAs involved in the expression of DNA damage proteins could be modulated in combination with PARP inhibitors to affect sensitivity to alkylating agents. · DOI · Paper page
  186. Kiltie, A. E. (ed.) Molecular Epidemiology of DNA Repair Genes in Bladder Cancer (Humana Press, Bethesda, 2009). · DOI
  187. Fenske, T. S. et al. Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. Cancer Res. 66, 5029–5038 (2006). · DOI
  188. Lutz, W. A true threshold dose in chemical carcinogenesis cannot be defined for a population, irrespective of the mode of action. Hum. Exp. Toxicol. 19, 566–568 (2000). · DOI
  189. Fry, R. C. et al. Genomic predictors of interindividual differences in response to DNA damaging agents. Genes Dev. 22, 2621–2626 (2008). · DOI
  190. Begley, T. J., Rosenbach, A. S., Ideker, T. & Samson, L. D. Hot spots for modulating toxicity identified by genomic phenotyping and localization mapping. Mol. Cell 16, 117–125 (2004). · DOI
  191. Ravi, D. et al. A network of conserved damage survival pathways revealed by a genomic RNAi screen. PLoS Genet. 5, e1000527 (2009). · DOI
  192. Robbins JH, Kraemer KH, Lutzner MA, Festoff BW & HG., C. Xeroderma pigmentosum. An inherited diseases with sun sensitivity, multiple cutaneous neoplasms, and abnormal DNA repair. Ann. Intern. Med. 80, 221–248 (1974). · DOI · Paper page
  193. Lovell, M. A., Xie, C. & Markesbery, W. R. Decreased base excision repair and increased helicase activity in Alzheimer's disease brain. Brain Res. 855, 116–123 (2000). · DOI · Paper page
  194. Weissman, L., de Souza-Pinto, N. C., Mattson, M. P. & Bohr, V. A. DNA base excision repair activities in mouse models of Alzheimer's disease. Neurobiol. Aging 30, 2080–2081 (2009). · DOI
  195. Iida, T., Furuta, A., Nishioka, K., Nakabeppu, Y. & Iwaki, T. Expression of 8-oxoguanine DNA glycosylase is reduced and associated with neurofibrillary tangles in Alzheimer's disease brain. Acta Neuropathol. 103, 20–25 (2002). · DOI
  196. Weissman, L. et al. Defective DNA base excision repair in brain from individuals with Alzheimer's disease and amnestic mild cognitive impairment. Nucleic Acids Res. 35, 5545–5555 (2007). · DOI · Paper page
  197. Hegde, M. L., Hazra, T. K. & Mitra, S. Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells. Cell Res. 18, 27–47 (2008). · DOI · Paper page
  198. Interthal, H. et al. SCAN1 mutant Tdp1 accumulates the enzyme-DNA intermediate and causes camptothecin hypersensitivity. EMBO J. 24, 2224–2233 (2005). · DOI · Paper page
  199. El-Khamisy, S. F. et al. Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature 434, 108–113 (2005). This important paper was the first to link SSB repair with neurodegeneration. · DOI · Paper page
  200. Lee, Y. et al. The genesis of cerebellar interneurons and the prevention of neural DNA damage require XRCC1. Nature Neurosci. 12, 973–980 (2009). · DOI

200 of 202 shown

Cited by

See all 947

Metadata

Authors
Fu, D., Calvo, J. A., & Samson, L. D.
Venue
Nature Reviews Cancer
Publisher
Springer Science and Business Media LLC
Published
2012-01-12
Volume
12
Issue
2
Pages
104-120
ISSN
  • 1474-175X
  • 1474-1768
DOI
10.1038/nrc3185
OpenAlex
W2094144162
Cited by
947
References
7
FWCI
21.03
Type
journal article
Language
en
Open access
green
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Balancing repair and tolerance of DNA damage caused by alkylating agents. https://app.cochat.ai/papers/10.1038/nrc3185
The paper
Fu, D., Calvo, J. A., & Samson, L. D. (2012). Balancing repair and tolerance of DNA damage caused by alkylating agents. Nature Reviews Cancer. https://doi.org/10.1038/nrc3185

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.